Effect of vitamin D
Journal
Antiviral therapy
ISSN: 2040-2058
Titre abrégé: Antivir Ther
Pays: England
ID NLM: 9815705
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
17
01
2021
pubmed:
12
3
2021
medline:
7
5
2022
entrez:
11
3
2021
Statut:
ppublish
Résumé
Both falls and fractures are increased in older persons living with HIV (PLWH). Low serum total 25-hydroxyvitamin D (25-OHD) levels have been associated with falls, fractures and poor muscle strength. We hypothesized that vitamin D (VitD) supplementation would improve muscle strength in postmenopausal PLWH. In a 12-month prospective, randomized, double-blind, study of 69 African American and Hispanic postmenopausal PLWH on antiretroviral therapy with 25-OHD ≥10 ng/ml and ≤32 ng/ml, we investigated the effects of daily low (1,000 IU; n=31) and moderate (3,000 IU; n=38) cholecalciferol doses on lean mass and strength. Change in lean body mass was assessed by dual-energy X-ray absorptiometry (DXA), and isometric and isokinetic muscle strength in the dominant lower extremity was assessed using the Biodex System 4 Pro. Mean age was 56 ±5 years, median CD4 VitD supplementation was associated with a modest increase in lower extremity strength in postmenopausal PLWH, without a concomitant increase in muscle mass. Magnitude of increase in strength were similar with 3,000 IU and 1,000 IU daily. Future larger studies will be required to determine the optimal dose of VitD to improve muscle strength and to determine whether supplementation reduces the risk of falls and fractures in PLWH.
Sections du résumé
BACKGROUND
Both falls and fractures are increased in older persons living with HIV (PLWH). Low serum total 25-hydroxyvitamin D (25-OHD) levels have been associated with falls, fractures and poor muscle strength. We hypothesized that vitamin D (VitD) supplementation would improve muscle strength in postmenopausal PLWH.
METHODS
In a 12-month prospective, randomized, double-blind, study of 69 African American and Hispanic postmenopausal PLWH on antiretroviral therapy with 25-OHD ≥10 ng/ml and ≤32 ng/ml, we investigated the effects of daily low (1,000 IU; n=31) and moderate (3,000 IU; n=38) cholecalciferol doses on lean mass and strength. Change in lean body mass was assessed by dual-energy X-ray absorptiometry (DXA), and isometric and isokinetic muscle strength in the dominant lower extremity was assessed using the Biodex System 4 Pro.
RESULTS
Mean age was 56 ±5 years, median CD4
CONCLUSIONS
VitD supplementation was associated with a modest increase in lower extremity strength in postmenopausal PLWH, without a concomitant increase in muscle mass. Magnitude of increase in strength were similar with 3,000 IU and 1,000 IU daily. Future larger studies will be required to determine the optimal dose of VitD to improve muscle strength and to determine whether supplementation reduces the risk of falls and fractures in PLWH.
Identifiants
pubmed: 33705355
doi: 10.3851/IMP3386
pmc: PMC9372923
mid: NIHMS1824030
doi:
Substances chimiques
Vitamin D
1406-16-2
Cholecalciferol
1C6V77QF41
Calcium Carbonate
H0G9379FGK
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-418Subventions
Organisme : NIAID NIH HHS
ID : K23 AI059884
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI065200
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Références
Antivir Ther. 2019;24(1):51-61
pubmed: 30604692
J Musculoskelet Neuronal Interact. 2015 Jun;15(2):145-53
pubmed: 26032206
Hormones (Athens). 2016 Oct;15(4):471-488
pubmed: 28222403
JAMA. 2005 May 11;293(18):2257-64
pubmed: 15886381
J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):342-349
pubmed: 30531305
J Clin Endocrinol Metab. 2014 Nov;99(11):4336-45
pubmed: 25033068
J Frailty Aging. 2016;5(1):43-8
pubmed: 26980368
J Clin Endocrinol Metab. 2006 Feb;91(2):405-12
pubmed: 16278262
Am J Epidemiol. 2004 Feb 15;159(4):413-21
pubmed: 14769646
J Clin Endocrinol Metab. 2013 Dec;98(12):E1927-35
pubmed: 24108316
J Bone Miner Res. 2007 Dec;22 Suppl 2:V59-63
pubmed: 18290724
J Gerontol A Biol Sci Med Sci. 2007 Nov;62(11):1279-86
pubmed: 18000149
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8
pubmed: 21118827
AIDS. 2017 Oct 23;31(16):2287-2294
pubmed: 28991026
HIV Med. 2016 Nov;17(10):740-748
pubmed: 27028463
J Frailty Aging. 2016;5(4):242-246
pubmed: 27883171
Arch Gerontol Geriatr. 2015 Sep-Oct;61(2):161-7
pubmed: 26164372
J Am Geriatr Soc. 2010 Nov;58(11):2063-8
pubmed: 21054285
Antivir Ther. 2016;21(8):697-706
pubmed: 27427794
J Gerontol A Biol Sci Med Sci. 2006 Mar;61(3):262-6
pubmed: 16567375
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Osteoporos Int. 2015 Oct;26(10):2413-21
pubmed: 25956283
Endocrinol Metab Clin North Am. 2017 Dec;46(4):919-933
pubmed: 29080643
J Clin Endocrinol Metab. 2011 Oct;96(10):2997-3006
pubmed: 21795448
Age (Dordr). 2016 Apr;38(2):36
pubmed: 26961694
JAMA. 2004 Apr 28;291(16):1999-2006
pubmed: 15113819